Stock AnalizMerck & Co. (MRK) earnings for the quarter ended September 2026: EPS beats estimates
Merck & Co. reported results for the quarter ended September 2026 on October 29, 2026. Adjusted earnings per share came in at $2.49 against the analysts’ average forecast of $2.08, a beat of 19.6%.
Revenue for the quarter was $18.09 billion, up 4.7% from $17.28 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 3.8% on the first trading day after the report.
The last four quarters
Merck & Co. has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $2.49 | $2.08 | +19.6% | +5% | +3.8% |
| Jun 2026 | -$0.13 | -$0.26 | +49.4% | +5% | +0.4% |
| Mar 2026 | -$1.28 | -$1.47 | +13.2% | +5% | +1.1% |
| Dec 2025 | $2.04 | $2.01 | +1.5% | +5% | +4.4% |
What comes next
Analysts expect EPS of $1.76 for the next quarter on average and $2.78 for the fiscal year ending December 31, 2026.
The average analyst price target is $161.53, 9% above the current price of $147.76.
Valuation and score
Merck & Co. scores 2.8 out of 5 overall on Stock Analiz (average), trades at a trailing P/E of about 150.8, and its intrinsic value under moderate assumptions is about 31% below the current market value. Full Merck & Co. analysis with 10 years of financials
Frequently asked questions
What was Merck & Co.’s EPS for the quarter ended September 2026?
$2.49 adjusted per share, against an analyst consensus of $2.08.
How much revenue did Merck & Co. report?
$18.09 billion, up 4.7% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.